New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
08:26 EDTICPT, GEVALeerink reiterates caution on Intercept ahead of FLINT data
Leerink says the physicians it spoke to at its Healthcare Insights Conference who treat liver diseases were cautious on Intercept's (ICPT) obeticholic acid's clinical potential in non-alcoholic steatohepatitis due to its effect on LDL-C. Leerink remains cautious on the stock ahead of full FLINT data in the second half of 2014, as it believes there is as much if not more downside than upside due to safety concerns. The firm adds the specialists noted that they have screened and not found any patients that warrant treatment with an expensive enzyme replacement therapy, such as Synageva's (GEVA) sebelipase alfa.
News For ICPT;GEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
16:48 EDTGEVASynageva sees FY15 operating expenses $280M-$25M
Subscribe for More Information
16:48 EDTGEVASynageva reports Q4 EPS ($1.73), consensus ($1.71)
Subscribe for More Information
February 23, 2015
08:09 EDTGEVASynageva announces FDA accepts accepts BLA filing for Kanuma
Subscribe for More Information
07:22 EDTGEVASunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
February 19, 2015
16:31 EDTICPTIntercept promotes Lisa Bright to Chief Commercial & Corporate Affairs Officer
Intercept Pharmaceuticals announced that Lisa Bright has been promoted to the newly-created position of Chief Commercial and Corporate Affairs Officer. Bright joined Intercept last year from Gilead Sciences where her leadership of the European launch of Sovaldi for the treatment of chronic hepatitis C contributed to the most successful product launch in pharmaceutical history.
February 18, 2015
07:36 EDTGEVASynageva European Patent issued for treatment of LAL deficiency
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use